Literature DB >> 6334132

Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis.

D J Brooks, K L Leenders, G Head, J Marshall, N J Legg, T Jones.   

Abstract

Regional cerebral oxygen utilisation (rCMRO2), oxygen extraction (rOER), blood flow (rCBF), and blood volume (rCBV) have been determined for fifteen patients with multiple sclerosis in remission using positron emission tomography (PET). Cerebral oxygen utilisation and blood flow were significantly reduced in both white matter and peripheral cortical grey matter in the multiple sclerosis patients compared to a group of normal controls. No evidence of regional cerebral ischaemia in the multiple sclerosis group was found. Lowest levels of cerebral oxygen utilisation were found in patients with cerebral atrophy, and in patients in whom a significant fall in present full-scale IQ from estimated pre-morbid levels had occurred. No correlation was found between rCMRO2 values and severity of locomotor dysfunction or clinical disease duration.

Entities:  

Mesh:

Year:  1984        PMID: 6334132      PMCID: PMC1028084          DOI: 10.1136/jnnp.47.11.1182

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin.

Authors:  M E Phelps; S C Huang; E J Hoffman; D E Kuhl
Journal:  J Nucl Med       Date:  1979-04       Impact factor: 10.057

2.  Quantitation in positron emission computed tomography: 1. Effect of object size.

Authors:  E J Hoffman; S C Huang; M E Phelps
Journal:  J Comput Assist Tomogr       Date:  1979-06       Impact factor: 1.826

3.  Cognitive, psychomotor, and motor correlates of multiple sclerosis.

Authors:  R M Reitan; J C Reed; M L Dyken
Journal:  J Nerv Ment Dis       Date:  1971-09       Impact factor: 2.254

4.  Cognitive functioning in multiple sclerosis.

Authors:  K L Jambor
Journal:  Br J Psychiatry       Date:  1969-07       Impact factor: 9.319

5.  Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test.

Authors:  H E Nelson; A O'Connell
Journal:  Cortex       Date:  1978-06       Impact factor: 4.027

6.  Exposure of multiple sclerosis patients to hyperbaric oxygen at 1.5--2 ATA. A preliminary report.

Authors:  R A Neubauer
Journal:  J Fla Med Assoc       Date:  1980-05

7.  Disability and intellectual function in multiple sclerosis patients.

Authors:  G G Marsh
Journal:  J Nerv Ment Dis       Date:  1980-12       Impact factor: 2.254

8.  Immunosuppression by hyperbaric oxygen.

Authors:  J F Hansbrough; J G Piacentine; B Eiseman
Journal:  Surgery       Date:  1980-06       Impact factor: 3.982

9.  Computer tomography of the cerebrum in multiple sclerosis.

Authors:  C Gyldensted
Journal:  Neuroradiology       Date:  1976-10-27       Impact factor: 2.804

10.  Cognitive function in patients with multiple sclerosis.

Authors:  J M Peyser; K R Edwards; C M Poser; S B Filskov
Journal:  Arch Neurol       Date:  1980-09
View more
  31 in total

1.  Magnetic resonance imaging reveals slow-down of global cerebral oxygen metabolism in multiple sclerosis.

Authors:  Risto A Kauppinen
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-04       Impact factor: 6.200

2.  Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T.

Authors:  Sumita Adhya; Glyn Johnson; Joseph Herbert; Hina Jaggi; James S Babb; Robert I Grossman; Matilde Inglese
Journal:  Neuroimage       Date:  2006-09-22       Impact factor: 6.556

3.  Multiple sclerosis and chronic cerebrospinal venous insufficiency: the neuroimaging perspective.

Authors:  M Filippi; M A Rocca; F Barkhof; R Bakshi; F Fazekas; O Khan; D Pelletier; A Rovira; J Simon
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-03       Impact factor: 3.825

4.  Veins in plaques of multiple sclerosis patients - a longitudinal magnetic resonance imaging study at 7 Tesla.

Authors:  Assunta Dal-Bianco; Simon Hametner; Günther Grabner; Melanie Schernthaner; Claudia Kronnerwetter; Andreas Reitner; Clemens Vass; Karl Kircher; Eduard Auff; Fritz Leutmezer; Karl Vass; Siegfried Trattnig
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

5.  Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis.

Authors:  M Filippi; C Tortorella; M Rovaris; M Bozzali; F Possa; M P Sormani; G Iannucci; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

6.  Multi-modal quantitative MRI investigation of brain tissue neurodegeneration in multiple sclerosis.

Authors:  Khader M Hasan; Indika S Walimuni; Humaira Abid; Jerry S Wolinsky; Ponnada A Narayana
Journal:  J Magn Reson Imaging       Date:  2012-01-12       Impact factor: 4.813

7.  Lateral ventricular cerebrospinal fluid diffusivity as a potential neuroimaging marker of brain temperature in multiple sclerosis: a hypothesis and implications.

Authors:  Khader M Hasan; John A Lincoln; Flavia M Nelson; Jerry S Wolinsky; Ponnada A Narayana
Journal:  Magn Reson Imaging       Date:  2014-12-05       Impact factor: 2.546

8.  Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis.

Authors:  Matilde Inglese; Sumita Adhya; Glyn Johnson; James S Babb; Laura Miles; Hina Jaggi; Joseph Herbert; Robert I Grossman
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-02       Impact factor: 6.200

9.  Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla.

Authors:  Yulin Ge; Vahe M Zohrabian; Etin-Osa Osa; Jian Xu; Hina Jaggi; Joseph Herbert; E Mark Haacke; Robert I Grossman
Journal:  J Magn Reson Imaging       Date:  2009-05       Impact factor: 4.813

10.  Structural brain correlates of anterograde memory deficits in multiple sclerosis.

Authors:  M Brainin; G Goldenberg; C Ahlers; T Reisner; A Neuhold; L Deecke
Journal:  J Neurol       Date:  1988-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.